T. Rowe Price Associates
RPTX

T. Rowe Price Associates’s Repare Therapeutics RPTX Stock Holding History

T. Rowe Price Associates’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-16,971
Closed -$206K – 2924
2023
Q3 		$206K Hold
16,971
– – ﹤0.01% 2492
2023
Q2 		$180K Sell
16,971
-9,923
-37% -$102K ﹤0.01% 2565
2023
Q1 		$265K Hold
26,894
– – ﹤0.01% 2406
2022
Q4 		$396K Buy
26,894
+8,567
+47% +$128K ﹤0.01% 2248
2022
Q3 		$223K Sell
18,327
-1,917,113
-99% -$24.7M ﹤0.01% 2505
2022
Q2 		$27.1M Sell
1,935,440
-152,905
-7% -$1.8M ﹤0.01% 1080
2022
Q1 		$29.7M Sell
2,088,345
-78,477
-4% -$1.16M ﹤0.01% 1130
2021
Q4 		$45.7M Buy
2,166,822
+250,849
+13% +$5.91M ﹤0.01% 1042
2021
Q3 		$50.3M Buy
1,915,973
+739,969
+63% +$23.9M ﹤0.01% 1011
2021
Q2 		$36.7M Buy
1,176,004
+1,121,157
+2,044% +$36.7M ﹤0.01% 1134
2021
Q1 		$1.68M Buy
54,847
+37,994
+225% +$1.29M ﹤0.01% 1801
2020
Q4 		$578K Buy
+16,853
New +$504K ﹤0.01% 2183

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

T. Rowe Price Associates's RPTX Position: Q4 2023 in Review

T. Rowe Price Associates sold out of Repare Therapeutics (RPTX) in Q4 2023, closing a stake of 16,971 shares — an estimated $206K sold.

T. Rowe Price Associates first reported a position in RPTX in Q4 2020 and held it in 12 quarters. The position peaked at $50.3M in Q3 2021. 69 funds tracked by Wall St. Rank hold RPTX as of Q4 2023.

  • T. Rowe Price Associates reported no remaining Repare Therapeutics position as of Q4 2023 after selling out during the quarter.
  • T. Rowe Price Associates sold 16,971 Repare Therapeutics shares in Q4 2023, an estimated $206K.
  • T. Rowe Price Associates first reported a position in Repare Therapeutics in Q4 2020 and held it in 12 quarters.
  • T. Rowe Price Associates's Repare Therapeutics position peaked at $50.3M in Q3 2021.
  • 69 funds tracked by Wall St. Rank held Repare Therapeutics as of Q4 2023.

Based on T. Rowe Price Associates's 13F filing for Q4 2023, filed 14 Feb 2024.